Navigation Links
Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
Date:8/4/2014

AUSTIN, Texas, Aug. 4, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Diagnostics Division is working on rapid diagnostics for the Ebola virus using Luminex xMAP® Technology. Luminex's MAGPIX® system was recently deployed to Africa to support research efforts to control the current outbreak. 

The recent Ebola outbreak has so far claimed 729 lives across Guinea, Liberia, Nigeria, and Sierra Leone according to the World Health Organization. Ebola virus disease is a severe, often fatal illness in humans characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. Early diagnosis is critical for proper management of the illness and prevention of spread.

Developed by USAMRIID Diagnostics Division and run on the MAGPIX system, the assays test serum samples for the presence of viral antigens (proteins) as well as antibodies directed at these antigens. Results of the assays provide information about replication of the virus and the immune response of the host, respectively. In a study conducted in rhesus macaques, Dr. Abbe Ames and colleagues showed that some animals may be able to limit the replication of the virus, and thus have a better chance of survival.1 Understanding the pathophysiology of the Ebola virus may assist in the development of countermeasures against the disease that could save lives.

"Our open architecture instruments provide researchers a flexible tool for assay development that can advance their research goals," said Patrick J. Balthrop, president and chief executive officer of Luminex. "Understanding the functional progression of a virus is extremely valuable information. Luminex is proud to support researchers, clinicians and biosurveillance professionals and their important work in the global effort to combat infectious diseases."

For more information on Luminex xMAP Technology and products, please visit the website at www.luminexcorp.com.

About Ebola Virus Disease (EVD)

Ebola virus disease is a severe, often fatal illness in humans. Outbreaks have a case fatality rate of up to 90% and occur primarily in remote villages in Central and West Africa, near tropical rainforests. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus. Severely ill patients require intensive supportive care. No licensed specific treatment or vaccine is available for use in people or animals.2 Because of the potential for human-to-human transmission, it is important to quickly identify infected individuals so proper precautions can be taken to limit spread of the disease.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

About USAMRIID

USAMRIID's mission is to protect the warfighter from biological threats and to be prepared to investigate disease outbreaks or threats to public health. Research conducted at USAMRIID leads to medical solutions-vaccines, drugs, diagnostics, and information-that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

References

1) http://globalbiodefense.com/2014/07/15/usamriid-providing-laboratory-support-ebola-outbreak/

2) Ebola virus disease. World Health Organization (Internet). Cited 2014 July. Available from: http://www.who.int/mediacentre/factsheets/fs103/en/.

Contacts:
Luminex Investor Contact
Harriss Currie, 512.219.8020
Sr. Vice President of Finance and CFO
hcurrie@luminexcorp.com

Luminex Media Contact
Mimi Torrington, 512.219.8020
Director of Marketing Communications
mtorrington@luminexcorp.com

Logo - http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO


'/>"/>
SOURCE Luminex Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Reports Second Quarter 2014 results
2. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
3. Luminex Corporation Reports Third Quarter 2013 Results
4. LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING
5. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
6. Luminex Corporation Reports Second Quarter 2013 Results
7. Luminex Corporation Achieves Milestone, Ships 10,000th Instrument
8. Luminex Corporation Second Quarter Earnings Release Scheduled for July 29, 2013
9. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
10. Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
11. Luminex Corporation To Present At Upcoming Investment Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... Chairman and CEO, will be presenting at Source Capital Group,s ... York, NY at 2:15 p.m. ET on Wednesday, ... Immunotherapy Panel discussion taking place at 3:15 p.m. ET. ... approximately one hour after the conclusion of the live event. ...
(Date:2/5/2016)... Feb. 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... previously announced underwritten secondary offering of 11,027,558 shares of ... of affiliates of Blackstone and Goldman Sachs.  The shares ... price of $96.45 per share. The selling stockholders will ... Zimmer Biomet nor any of its directors, officers or ...
(Date:2/5/2016)... France , Germany ... and Israel ). It includes a 10-year epidemiology forecast ... segmented by age and sex in these markets. GD epidemiology report is ... in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends ... Germany , Italy , Spain ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV ... the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream ... Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... to announce the addition of micro-needling services in their Napa Valley office. The ... founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: ... wait longer to access the treadmills. It’s a predictable trend. After the excesses of ... and get in shape by joining gyms, starting new walking or running routines, or ...
(Date:2/5/2016)... , ... February 05, 2016 , ... At its annual ... Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former ... the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has ...
Breaking Medicine News(10 mins):